Evolving Long‐Term Outcomes of Heart Transplantation Using COVID‐19 Positive Donors
Clinical Transplantation · 2026
DOI: 10.1111/ctr.70439 ↗At a glance
Journal article in Clinical Transplantation, 2026. Written by Ye In Christopher Kwon and 12 co-authors. Institution: Division of Cardiothoracic Surgery, Department of Surgery, Pauley Heart Center, School of Medicine, Virginia Commonwealth University, Richmond, Virgi…. Major MEDLINE topics: Heart Transplantation, COVID-19, Tissue Donors, Graft Rejection. 37 references.
Abstract (original language)
Background
As COVID‐19 becomes endemic, evaluating COVID‐19+ donors for heart transplantation (HT) remains important. We assessed long‐term outcomes using national data and propensity‐matched analysis.
Methods
All adults (>18 years) undergoing HT between 4/2020 and 9/2024 were identified in the UNOS database. They were stratified into COVID‐19+ versus –, defined by either a positive nucleic acid or antigen test within 7 days of HT. Groups were then 3:1 nearest propensity score matched. Survival was estimated by the Kaplan–Meier method. Mortality risk was assessed using Cox regression models.
Results
A total of 879 recipients of COVID‐19– hearts were matched with 293 recipients of COVID‐19+ hearts. We found no significant differences in 3‐year landmark survival between cohorts ( p = 0.23). Rates of acute rejection ( p = 0.15), length of hospital stay (LOS) ( p > 0.9), and postoperative stroke ( p = 0.53) did not differ significantly between groups. However, dialysis (17% vs. 12%, p = 0.04) and primary graft dysfunction rates at 24‐h post‐HT were significantly higher in COVID‐19+ heart recipients (5.5% vs. 1.8%, p = 0.01). Donor COVID‐19+ status was not significantly associated with mortality risk (HR 1.01, p = 0.66). COVID‐19+ donor HTs in recent years (2022–2024) were associated with decreased mortality risk (HR 0.82, p = 0.02), rates of acute rejection ( p < 0.001), LOS ( p = 0.01), and dialysis (18% vs. 8.9%, p = 0.03).
Conclusions
COVID‐19+ hearts demonstrate adequate long‐term outcomes, particularly in recent years. Future studies should assess the impact of donor vaccination to optimize survival benefits.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Division of Cardiothoracic Surgery, Department of Surgery, Pauley Heart Center, School of Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.
- School of Medicine, University of Virginia, Charlottesville, Virginia, USA.
- Department of Biostatistics, School of Population Health, Virginia Commonwealth University, Richmond, Virginia, USA.
ORCID profiles: Ye In Christopher Kwon, David T Zhu, Alan Lai, Matthew Ambrosio, Zachary Fitch, Josue Chery, Vigneshwar Kasirajan, Zubair A Hashmi
Cite
APA
Kwon, Y. I. C., Bao, B., Guiry, J., Zhu, D. T., Lai, A., Ambrosio, M., Kesari, A., Patel, J., Fitch, Z., Chery, J., Nicolato, P., Kasirajan, V., & Hashmi, Z. A. (2026). Evolving Long‐Term Outcomes of Heart Transplantation Using COVID‐19 Positive Donors. Clinical Transplantation. https://doi.org/10.1111/ctr.70439
Vancouver
Kwon YIC, Bao B, Guiry J, Zhu DT, Lai A, Ambrosio M, et al. Evolving Long‐Term Outcomes of Heart Transplantation Using COVID‐19 Positive Donors. Clinical Transplantation. 2026. doi:10.1111/ctr.70439
BibTeX
@article{Kwon2026,
author = {Kwon, Ye In Christopher and Bao, Brian and Guiry, Jack and Zhu, David T and Lai, Alan and Ambrosio, Matthew and Kesari, Aditya and Patel, Jay and Fitch, Zachary and Chery, Josue and Nicolato, Patricia and Kasirajan, Vigneshwar and Hashmi, Zubair A},
title = {Evolving Long‐Term Outcomes of Heart Transplantation Using COVID‐19 Positive Donors},
journal = {Clinical Transplantation},
year = {2026},
doi = {10.1111/ctr.70439}
}
EUVIMED